1. APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid1
- Author
-
John Park, and Alzheimer’s Disease Neuroimaging Initiative, Jennifer L. Modliszewski, Arthur Moseley, Michael W. Lutz, Ashley Hall, Stacey Chung, Jeffrey N. Browndyke, Alexander S. Roesler, Victor Cai, Miles Berger, Keith W. VanDusen, Michael J. Devinney, J. Will Thompson, Mary Cooter, Shayan Smani, and David L. Corcoran
- Subjects
0301 basic medicine ,False discovery rate ,biology ,General Neuroscience ,Neurodegeneration ,C-reactive protein ,General Medicine ,medicine.disease ,Complement system ,03 medical and health sciences ,Psychiatry and Mental health ,Clinical Psychology ,030104 developmental biology ,0302 clinical medicine ,Cerebrospinal fluid ,mental disorders ,Immunology ,medicine ,biology.protein ,Biomarker (medicine) ,Geriatrics and Gerontology ,Alzheimer's disease ,030217 neurology & neurosurgery ,Neuroinflammation - Abstract
Background: APOE4 has been hypothesized to increase Alzheimer’s disease risk by increasing neuroinflammation, though the specific neuroinflammatory pathways involved are unclear. Objective: Characterize cerebrospinal fluid (CSF) proteomic changes related to APOE4 copy number. Methods: We analyzed targeted proteomic data from ADNI CSF samples using a linear regression model adjusting for age, sex, and APOE4 copy number, and additional linear models also adjusting for AD clinical status or for CSF Aβ, tau, or p-tau levels. False discovery rate was used to correct for multiple comparisons correction. Results: Increasing APOE4 copy number was associated with a significant decrease in a CRP peptide level across all five models (q
- Published
- 2021
- Full Text
- View/download PDF